A Phase 2 Dose Ranging, Randomized, Double Blind, and Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Non-Alcoholic Steatohepatitis (NASH)
Phase of Trial: Phase II
Latest Information Update: 04 Apr 2018
At a glance
- Drugs EDP 305 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Acronyms ARGON-1
- Sponsors Enanta Pharmaceuticals
- 27 Mar 2018 Planned primary completion date changed from 1 Apr 2019 to 1 Mar 2019.
- 01 Feb 2018 Status changed from planning to recruiting.
- 12 Jan 2017 New trial record